Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study-Reference-Cited by-同舟云学术

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

Published:2016-12-19 Issue:2 Volume:40 Page:153-167
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Lantinga Marten A.,D’Agnolo Hedwig M. A.,Casteleijn Niek F.,de Fijter Johan W.,Meijer Esther,Messchendorp Annemarie L.,Peters Dorien J. M.,Salih Mahdi,Spithoven Edwin M.,Soonawala Darius,Visser Folkert W.,Wetzels Jack F. M.,Zietse Robert,Drenth Joost P. H.,Gansevoort Ron T.,Drenth J. P. H.,de Fijter J. W.,Gansevoort R. T.,Peters D. J. M.,Wetzels J.,Zietse R.,

Funder

Nierstichting

Ipsen Farmaceutica B.V.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-016-0486-x.pdf

Reference33 articles.

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–301.

2. Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1(1):64–9.